Stay updated on Pembrolizumab in NSCLC with PS 2 Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in NSCLC with PS 2 Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.5.5, indicating a small update to the site, with no visible changes to the study information.
    Difference
    0.1%
    Check dated 2026-06-05T12:33:40.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Revision: v3.5.4 has been added, replacing Revision: v3.5.3. This change updates the page's version metadata rather than its visible content or behavior.
    Difference
    0.1%
    Check dated 2026-05-15T05:51:39.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    The page’s UI/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a backend or display release rather than a change to the study record content.
    Difference
    0.1%
    Check dated 2026-04-24T06:14:26.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:41:38.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-19T06:11:53.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.1%
    Check dated 2026-03-12T02:52:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in NSCLC with PS 2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.